Key facts
- U.S. prescription drug prices fell 0.8% in July and 3.1% year-over-year, the steepest drop since 1963.
- The White House attributed the price decline to President Trump's 'most favored nation' drug deals and the TrumpRx website.
- Experts point to market competition, generic/biosimilar drugs, and the Inflation Reduction Act's Medicare negotiation provisions as key factors.
- The Labor Department's price index measures pharmacy payouts, not direct consumer costs, making the impact on individuals uncertain.
- The actual impact of 'most favored nation' deals remains unclear as contracts are not public and implementation is pending.
President Donald Trump has claimed credit for a significant drop in U.S. prescription drug prices, citing new federal data showing a 0.8% decrease in July and a 3.1% decline year-over-year. The White House attributed these reductions to the president's 'most favored nation' drug deals and the TrumpRx website, asserting they are providing real relief to American families.
However, drug pricing experts suggest a more complex reality. They point to the Inflation Reduction Act, enacted under President Joe Biden, which allows Medicare to negotiate drug prices, as a potentially more significant factor. The introduction of generic and biosimilar products, offering cheaper alternatives to expensive brand-name and biologic drugs, is also cited as a key driver of price decreases.
Experts like Juliette Cubanski of KFF noted that the Labor Department's prescription drug price index measures what pharmacies are paid, not necessarily what consumers directly pay, making it difficult to ascertain the precise impact on individuals. Dr. Benjamin Rome of Harvard Medical School highlighted how generic competition for blockbuster drugs leads to price drops, a phenomenon also observed with drugs like Humira and Stelara.
Stacie Dusetzina from Vanderbilt University School of Medicine indicated that the impact of Trump's 'most favored nation' deals is unclear, as the contracts are not public and their implementation models have not yet affected payers. She believes the Inflation Reduction Act's policies are more directly responsible for the observed price changes.
While TrumpRx is recognized for promoting price transparency, its actual usage and the claimed $700 million in savings have been questioned, notably by Senator Elizabeth Warren, who cited Health Secretary Robert F. Kennedy Jr.'s admission that the website does not store patient data, rendering savings claims unreliable.
Furthermore, experts caution that consumers may not be experiencing these price reductions directly. The index's measurement method means insurers often absorb costs, and individual patient costs depend on insurance plans. Additionally, rising overall health costs and insurance premiums could offset any savings on prescription drugs for many Americans.